Dyne Therapeutics, Inc.NASDAQ: DYN

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Dyne Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Dyne Therapeutics, a clinical-stage company developing treatments for genetically driven neuromuscular diseases, granted inducement equity awards to 17 newly hired employees as an incentive to join, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key details

  • The awards include non-statutory stock options to buy up to an aggregate of 213,000 shares of common stock, at an exercise price equal to the closing price on The Nasdaq Global Select Market on November 17, 2026.
  • The awards also include restricted stock units (rights to receive shares later) covering an aggregate of 67,200 shares of common stock.
  • The options have a ten-year term and vest over four years: 25% on the first anniversary of each employee's start date, with the rest in 12 equal quarterly installments after that.
  • The restricted stock units vest in four equal annual installments over four years from each employee's start date.
  • The awards are subject to award agreements and Dyne's 2024 Inducement Stock Incentive Plan.

What’s still pending

  • Vesting of both the options and the restricted stock units depends on each employee's continued service to Dyne through the applicable vesting dates.

6ix AI wrote this summary from the release below and checked it against the release.

WALTHAM, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 213,000 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on November 17, 2026, and restricted stock units with respect to an aggregate of 67,200 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
[email protected]781-317-0353

Media
Stacy Nartker
[email protected]
781-317-1938

View original source (GlobeNewswire)Dyne Therapeutics, Inc. on 6ix

Story so far

Earlier from Dyne Therapeutics

All Dyne Therapeutics news releases